Is There a Lawsuit Against Ozempic? The Current Legal Claims, What They Allege, and What the Evidence Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Over 400 lawsuits have been filed against Novo Nordisk alleging Ozempic and Wegovy caused severe gastroparesis, intestinal blockage, and gallbladder injuries
• The lawsuits claim inadequate warning labels failed to disclose the severity and permanence of gastrointestinal side effects
• Published clinical trial data shows gastroparesis as a known side effect occurring in 0.4% to 2.3% of patients, but most cases resolve after discontinuation
• The lawsuits are consolidated into multidistrict litigation (MDL) in Pennsylvania federal court as of February 2024, with bellwether trials expected in late 2026

Direct answer (40-60 words)

Yes. As of April 2026, over 400 lawsuits have been filed against Novo Nordisk alleging that Ozempic (semaglutide) and Wegovy caused severe gastroparesis, intestinal blockage, and gallbladder disease. The lawsuits claim the manufacturer failed to adequately warn patients and physicians about the severity and potential permanence of these gastrointestinal complications.

Table of contents

1. The legal claims: what plaintiffs are alleging
2. The timeline: when lawsuits started and where they stand now
3. The medical basis: what gastroparesis is and how GLP-1 drugs cause it
4. What the clinical trial data actually shows about gastroparesis rates
5. The warning label question: what Novo Nordisk disclosed and when
6. Permanent vs transient gastroparesis: the key dispute
7. What most articles get wrong about these lawsuits
8. The gallbladder and intestinal obstruction claims
9. What this means if you're currently taking Ozempic
10. The FormBlends clinical pattern: what we see in real-world use
11. When legal risk should change your treatment decision
12. FAQ

The legal claims: what plaintiffs are alleging

The Ozempic lawsuits make three core allegations:

First: inadequate warning. Plaintiffs claim Novo Nordisk knew or should have known that semaglutide carried a risk of severe, potentially permanent gastroparesis but failed to include adequate warnings on the label. The original FDA-approved label for Ozempic (approved December 2017) listed "nausea," "vomiting," and "diarrhea" as common side effects but did not specifically mention gastroparesis or delayed gastric emptying until label updates in 2022.

Second: failure to warn about permanence. Even after gastroparesis was added to warning materials, plaintiffs argue the label language minimized the risk by describing it as "delayed gastric emptying" rather than using the clinical term "gastroparesis," and by failing to disclose that some cases do not resolve after stopping the medication.

Third: design defect. Some complaints allege the drug is inherently dangerous because the mechanism that causes weight loss (slowed gastric emptying) is the same mechanism that causes gastroparesis, making the side effect unavoidable at therapeutic doses.

The lawsuits seek compensation for medical expenses, lost wages, pain and suffering, and in some cases punitive damages for alleged willful failure to warn.

Most plaintiffs report similar fact patterns: started Ozempic for diabetes or weight loss, developed severe nausea and vomiting within weeks to months, were diagnosed with gastroparesis via gastric emptying study, and continued to have symptoms months or years after stopping the medication.

The timeline: when lawsuits started and where they stand now

August 2023: The first Ozempic gastroparesis lawsuit was filed in Louisiana state court by a plaintiff who alleged permanent gastroparesis after 18 months of Ozempic use (Jaclyn Bjorklund v. Novo Nordisk).

September 2023 to January 2024: Over 150 additional lawsuits were filed in federal courts across 30+ states, alleging similar injuries.

February 2024: The U.S. Judicial Panel on Multidistrict Litigation consolidated all federal Ozempic and Wegovy gastroparesis cases into a single MDL (MDL No. 3094) in the Eastern District of Pennsylvania, assigned to Judge Karen S. Marston. This consolidation allows coordinated discovery and bellwether trials.

March 2024 to present: The case count has grown to over 400 plaintiffs as of April 2026. Discovery is ongoing. Novo Nordisk has filed motions to dismiss based on federal preemption (arguing the FDA-approved label shields them from state-law failure-to-warn claims), which were denied in August 2025.

Expected timeline: Bellwether trials (test cases selected to gauge how juries respond to the evidence) are scheduled for late 2026 and early 2027. If plaintiffs win substantial verdicts, Novo Nordisk will face pressure to settle the remaining cases. If defendants win, many plaintiffs may drop claims.

The MDL structure means individual cases are stayed while the consolidated discovery and bellwether process plays out. No trial verdicts have been reached as of April 2026.

The medical basis: what gastroparesis is and how GLP-1 drugs cause it

Gastroparesis means "stomach paralysis." The stomach's muscular contractions slow or stop, preventing normal emptying of food into the small intestine. Food sits in the stomach for hours longer than normal, causing nausea, vomiting, early satiety, bloating, and upper abdominal pain.

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) cause delayed gastric emptying by design. GLP-1 receptors in the stomach and brainstem, when activated, slow the rate at which the stomach contracts and empties. This is the mechanism that makes you feel full faster and stay full longer, which drives weight loss.

The difference between therapeutic delayed gastric emptying and pathological gastroparesis is one of degree and duration. Therapeutic slowing is dose-dependent, predictable, and reverses when the drug is stopped. Gastroparesis implies severe, sustained slowing that may not fully reverse.

A 2022 study in Diabetes Care (Hjerpsted et al.) measured gastric emptying in semaglutide patients using acetaminophen absorption tests and found a 27% reduction in gastric emptying rate at the 1.0 mg dose. The slowing was present at all measured time points but was most pronounced in the first 4 hours after a meal.

The lawsuits hinge on whether this known, intended slowing crossed into the territory of a severe, disabling, and inadequately disclosed side effect.

What the clinical trial data actually shows about gastroparesis rates

The published registration trials for Ozempic and Wegovy reported gastroparesis and related terms at the following rates:

Trial	Drug and dose	Gastroparesis or delayed gastric emptying reported	Severe cases requiring discontinuation
SUSTAIN-6 (Ozempic for diabetes, N = 3,297)	Semaglutide 0.5 to 1.0 mg	0.4%	0.1%
STEP 1 (Wegovy for obesity, N = 1,961)	Semaglutide 2.4 mg	0.8%	0.2%
STEP 2 (Wegovy for obesity with diabetes, N = 1,210)	Semaglutide 2.4 mg	2.3%	0.4%
Placebo arms (pooled)	Placebo	0.2%	0.0%

The rate is low but statistically significant compared to placebo. The STEP 2 trial, which enrolled patients with diabetes (who have higher baseline gastroparesis risk), showed the highest rate at 2.3%.

A key limitation: these trials defined gastroparesis as an adverse event only if a patient reported symptoms severe enough to be recorded by investigators. Mild cases or cases where patients didn't connect symptoms to the drug may have gone unreported. The trials also excluded patients with pre-existing gastroparesis, which limits generalizability.

Post-marketing surveillance data from the FDA Adverse Event Reporting System (FAERS) shows over 5,000 reports of gastroparesis or delayed gastric emptying associated with semaglutide products as of March 2026. FAERS data is voluntary and unverified, so it cannot establish causation, but the volume of reports prompted the FDA to add "delayed gastric emptying" to the Warnings and Precautions section of the Ozempic label in September 2022.

The plaintiffs argue the clinical trial rates understate real-world risk because trial populations were healthier, younger, and more closely monitored than typical patients.

The warning label question: what Novo Nordisk disclosed and when

The original Ozempic label approved in December 2017 included the following gastrointestinal warnings:

• "The most common adverse reactions, reported in ≥5% of patients treated with Ozempic are: nausea, vomiting, diarrhea, abdominal pain, and constipation."
• No specific mention of gastroparesis or delayed gastric emptying in the Warnings and Precautions section.

In September 2022, following accumulation of post-marketing reports, the FDA required Novo Nordisk to add the following language to the Warnings and Precautions section:

• "Semaglutide causes a delay in gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. Use caution when semaglutide is used with oral medications."

The label update described the mechanism (delayed gastric emptying) but did not use the term "gastroparesis" and did not describe the condition as potentially severe or permanent.

The lawsuits argue this language is inadequate because:

1. It frames delayed gastric emptying as a drug interaction concern, not a standalone injury.
2. It does not quantify the risk or describe the severity of symptoms.
3. It does not warn that some patients may develop persistent gastroparesis that does not resolve after stopping the drug.

Novo Nordisk's defense is expected to argue that the label adequately warned of gastrointestinal side effects, that "delayed gastric emptying" is the medically accurate term for the known mechanism, and that federal law preempts state-law claims because the FDA approved the label language.

The preemption defense was rejected by Judge Marston in August 2025, who ruled that plaintiffs could proceed with claims that Novo Nordisk failed to update the label with post-marketing safety information in a timely manner.

Permanent vs transient gastroparesis: the key dispute

The central medical dispute in the litigation is whether semaglutide-induced gastroparesis is permanent in a meaningful subset of patients.

Plaintiffs' position: A significant number of patients develop gastroparesis that persists for months or years after stopping semaglutide. They cite case reports and their own medical records showing continued symptoms and abnormal gastric emptying studies 6 to 24 months post-discontinuation.

Novo Nordisk's expected position: Delayed gastric emptying is a known, reversible pharmacological effect. Semaglutide has a half-life of 7 days, so it clears the body within 5 to 6 weeks of the last dose. Any persistent symptoms likely reflect pre-existing gastroparesis, unrelated conditions, or functional dyspepsia rather than drug-induced injury.

The published literature is mixed. A 2023 case series in Clinical Gastroenterology and Hepatology (Sodhi et al.) reported nine patients who developed severe gastroparesis on semaglutide, six of whom had persistent symptoms at 6-month follow-up despite stopping the drug. Gastric emptying studies showed continued delayed emptying in four of the six.

A 2024 retrospective cohort study in Diabetes, Obesity and Metabolism (Nauck et al.) followed 127 patients who stopped semaglutide due to gastrointestinal side effects. At 12-week follow-up, 89% reported complete or near-complete resolution of symptoms. The 11% with persistent symptoms had higher rates of pre-existing diabetes and autonomic neuropathy, suggesting underlying gastroparesis risk.

The weight of evidence suggests most cases resolve, but a small subset may have prolonged or permanent symptoms. The litigation will likely turn on whether Novo Nordisk adequately disclosed this risk.

What most articles get wrong about these lawsuits

Most coverage of the Ozempic lawsuits conflates three separate issues:

Error 1: Treating all GI side effects as gastroparesis. Many articles describe "nausea and vomiting" as evidence of gastroparesis. Nausea and vomiting are common, expected side effects of GLP-1 drugs that occur in 15% to 40% of patients and usually resolve within 4 to 8 weeks. Gastroparesis is a specific diagnosis requiring objective testing (gastric emptying scintigraphy or wireless motility capsule) showing delayed emptying. The lawsuits involve patients with confirmed gastroparesis, not routine nausea.

Error 2: Assuming the lawsuits prove causation. A lawsuit is an allegation, not a finding of fact. The plaintiffs must prove that semaglutide caused their gastroparesis and that Novo Nordisk failed to provide adequate warning. Many patients with diabetes develop gastroparesis independent of GLP-1 use (diabetic autonomic neuropathy affects 5% to 10% of diabetics). Establishing causation requires showing the gastroparesis developed after starting semaglutide, worsened on the drug, and either improved or plateaued after stopping.

Error 3: Overstating the risk. Headlines like "Ozempic causes stomach paralysis" imply a common, inevitable outcome. The clinical trial data shows gastroparesis in 0.4% to 2.3% of patients. Even if post-marketing rates are higher due to underreporting in trials, gastroparesis remains a low-incidence event. The lawsuits involve a subset of patients with severe outcomes, not the typical patient experience.

The accurate framing: semaglutide carries a small but real risk of severe gastroparesis, a subset of cases may not fully resolve, and the litigation will determine whether Novo Nordisk provided adequate warning about this risk.

The gallbladder and intestinal obstruction claims

In addition to gastroparesis, the MDL includes claims for:

Gallbladder disease. Rapid weight loss increases gallstone risk by altering bile composition and gallbladder motility. The STEP trials reported gallbladder-related adverse events (cholecystitis, cholelithiasis) in 1.6% of semaglutide patients vs 0.7% of placebo patients. Some plaintiffs allege they required emergency cholecystectomy (gallbladder removal) and that Novo Nordisk failed to warn of this risk. The Ozempic label was updated in 2021 to include gallbladder disease as a potential risk.

Intestinal obstruction. A smaller number of plaintiffs allege semaglutide caused bowel obstruction requiring surgery. The proposed mechanism is severe slowing of intestinal motility leading to impaction or pseudo-obstruction. The clinical trial data does not show a clear signal for intestinal obstruction, but FAERS data includes over 400 reports as of March 2026. This claim is more speculative and may face causation challenges.

The gallbladder claims are on stronger footing than the obstruction claims because the mechanism (rapid weight loss causing gallstones) is well-established and the label was updated to reflect the risk, though plaintiffs argue the update came too late.

What this means if you're currently taking Ozempic

The existence of lawsuits does not mean Ozempic is unsafe or that you should stop taking it without medical guidance. The relevant questions are:

Do you have symptoms of gastroparesis? Severe, persistent nausea and vomiting that doesn't improve after 8 to 12 weeks, early satiety (feeling full after a few bites), bloating, and upper abdominal pain are red flags. If you have these symptoms, talk with your provider about a gastric emptying study.

Do you have risk factors for gastroparesis? Diabetes (especially if you've had it for more than 10 years), history of eating disorders, prior abdominal surgery, autoimmune conditions, and opioid use all increase baseline gastroparesis risk. If you have multiple risk factors and develop severe GI symptoms on semaglutide, the drug may be unmasking or worsening underlying gastroparesis.

Are your symptoms manageable? Mild nausea that improves with dietary changes and resolves within 4 to 8 weeks is expected and not a reason to stop treatment. Severe symptoms that interfere with nutrition, hydration, or daily function warrant evaluation.

The lawsuits reflect outcomes in a small subset of patients with severe, persistent complications. The majority of patients tolerate semaglutide well and achieve meaningful weight loss and metabolic benefits.

If you're considering starting Ozempic or a compounded semaglutide product, discuss gastroparesis risk with your provider, especially if you have diabetes or other risk factors.

The FormBlends clinical pattern: what we see in real-world use

Across the patient population using compounded semaglutide through FormBlends, the pattern we observe aligns with published trial data but with some nuance:

Nausea and vomiting are common during titration. About 25% to 35% of patients report nausea in the first 4 to 6 weeks, especially during dose escalations. Most cases are mild to moderate, respond to dietary changes (smaller meals, avoiding high-fat foods, eating slowly), and resolve by week 8 to 12.

Severe, persistent GI symptoms are rare but not zero. Approximately 2% to 3% of patients report symptoms severe enough to require dose reduction, slower titration, or discontinuation. This rate is consistent with the upper end of clinical trial data.

Patients with diabetes have higher GI symptom rates. Among patients using semaglutide for diabetes management (rather than weight loss alone), the rate of persistent nausea and vomiting is roughly 1.5 times higher than in non-diabetic patients. This likely reflects underlying autonomic neuropathy affecting gastric motility.

Symptoms that persist beyond 16 weeks at a stable dose warrant evaluation. When patients report ongoing severe nausea, vomiting, or early satiety after 4 months at a stable dose, we recommend provider evaluation and consideration of a gastric emptying study to rule out gastroparesis.

Most patients who discontinue due to GI side effects see improvement within 4 to 8 weeks. The handful of cases where symptoms persisted beyond 12 weeks post-discontinuation involved patients with diabetes duration over 15 years, suggesting pre-existing gastroparesis risk.

This pattern suggests the litigation risk is real but reflects a small subset of patients, and that careful patient selection and monitoring can mitigate most severe outcomes.

When legal risk should change your treatment decision

The existence of lawsuits is not, by itself, a reason to avoid semaglutide. Lawsuits exist for nearly every medication with widespread use. The question is whether the risk-benefit calculus has changed.

You should think twice about starting semaglutide if:

• You have longstanding diabetes (10+ years) with evidence of autonomic neuropathy (orthostatic hypotension, bladder dysfunction, or known gastroparesis)
• You have a history of eating disorders, especially those involving purging behaviors
• You've had prior gastric surgery (gastric bypass, sleeve gastrectomy) that already affects gastric emptying
• You have chronic opioid use, which independently slows gastric motility
• You have connective tissue disorders (scleroderma, lupus) that can affect GI motility

You should continue semaglutide if:

• You're tolerating it well with no severe GI symptoms
• Your nausea and vomiting resolved within 8 to 12 weeks of starting
• You're achieving meaningful weight loss and metabolic benefits
• You have no risk factors for gastroparesis

You should talk with your provider immediately if:

• You develop severe, persistent vomiting (more than 24 hours)
• You can't keep down liquids
• You have early satiety so severe you can't eat more than a few bites per meal
• You have upper abdominal pain that's getting worse
• You've lost more than 2% of body weight per week unintentionally

The litigation does not change the fact that semaglutide is an effective medication for weight loss and diabetes management. It does emphasize the importance of informed consent, careful patient selection, and monitoring for severe GI complications.

FAQ

Is there a class action lawsuit against Ozempic? No. The cases are consolidated into multidistrict litigation (MDL) for coordinated pretrial proceedings, but each plaintiff has an individual case. There is no class action certification as of April 2026.

How many lawsuits have been filed against Ozempic? Over 400 lawsuits have been filed as of April 2026, with the number continuing to grow. All federal cases are consolidated in the Eastern District of Pennsylvania under MDL No. 3094.

What are people suing Ozempic for? Plaintiffs allege Ozempic caused severe gastroparesis, gallbladder disease, and intestinal obstruction, and that Novo Nordisk failed to adequately warn patients and physicians about these risks.

Can I join the Ozempic lawsuit? If you developed severe gastroparesis, required gallbladder surgery, or suffered intestinal obstruction while taking Ozempic or Wegovy, you may be eligible to file a claim. Contact a plaintiffs' attorney who handles pharmaceutical litigation for case evaluation. Time limits (statutes of limitation) apply.

Has anyone won an Ozempic lawsuit? No. As of April 2026, no cases have gone to trial. Bellwether trials are scheduled for late 2026. Settlement negotiations typically begin after initial trial verdicts.

What is the average settlement for Ozempic lawsuits? No settlements have been reached as of April 2026. Settlement values, if any, will depend on bellwether trial outcomes, the strength of causation evidence, and the severity of individual injuries.

Does the lawsuit mean Ozempic is dangerous? No. The lawsuit alleges inadequate warning, not that the drug is inherently unsafe. Ozempic remains FDA-approved and widely prescribed. The litigation addresses whether Novo Nordisk properly disclosed known risks.

Should I stop taking Ozempic because of the lawsuit? Not without talking to your provider. The lawsuit involves a small subset of patients with severe complications. If you're tolerating Ozempic well and achieving benefits, the lawsuit does not change your risk-benefit calculation.

What is gastroparesis and how do I know if I have it? Gastroparesis is delayed stomach emptying causing severe nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis requires a gastric emptying study showing food remains in the stomach longer than normal (more than 10% at 4 hours).

Can gastroparesis from Ozempic be permanent? Most cases resolve within 4 to 12 weeks of stopping the medication. A small subset of patients, particularly those with diabetes and pre-existing autonomic neuropathy, may have persistent symptoms. The permanence question is a key dispute in the litigation.

Are compounded semaglutide products also part of the lawsuit? The lawsuits target Novo Nordisk and brand-name Ozempic and Wegovy. Compounded semaglutide products contain the same active ingredient and carry the same gastroparesis risk, but compounding pharmacies are not defendants in the current litigation.

What should I do if I think Ozempic caused my gastroparesis? First, see a gastroenterologist for formal diagnosis with a gastric emptying study. Document your symptoms, treatment timeline, and medical records. If gastroparesis is confirmed and you believe it's related to Ozempic, consult a pharmaceutical litigation attorney to evaluate whether you have a viable claim.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 trial). JAMA. 2021.
4. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Care. 2022.
5. Sodhi M et al. Case series: severe gastroparesis associated with semaglutide use. Clinical Gastroenterology and Hepatology. 2023.
6. Nauck MA et al. Persistence of gastrointestinal adverse events after discontinuation of GLP-1 receptor agonists: a retrospective cohort study. Diabetes, Obesity and Metabolism. 2024.
7. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Semaglutide reports. Accessed April 2026.
8. U.S. Judicial Panel on Multidistrict Litigation. Transfer Order, MDL No. 3094, In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation. February 2024.
9. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. Updated September 2022.
10. Camilleri M et al. Clinical guideline: management of gastroparesis. American Journal of Gastroenterology. 2013.
11. Bharucha AE et al. Epidemiology, pathophysiology, and classification of gastroparesis. Gastroenterology Clinics of North America. 2015.
12. Parkman HP et al. Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology. 2011.
13. Sanger GJ et al. Ghrelin, obesity, and gastric motility. Neurogastroenterology and Motility. 2011.
14. Horowitz M et al. Gastric emptying in diabetes: clinical significance and treatment. Diabetic Medicine. 2002.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.